
    
      A randomized prospective study of administration of Degarelix in late luteal phase of women
      undergoing ovarian stimulation for IVF: Single dose of Degarelix (24mg, 16mg or 12 mg), on
      day 24th of previous luteal face cycle, was administered. The Clinical Pregnancy and Live
      Birth Rates were estimated for this group of patients, comparing to the rates of the group
      which followed classical antagonist protocol. The number of the formed blastocysts in each
      group is measured, as well.
    
  